发明名称 Pegylated L-asparaginase
摘要 Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.
申请公布号 US2016060613(A1) 申请公布日期 2016.03.03
申请号 US201514819305 申请日期 2015.08.05
申请人 ALIZE PHARMA II SAS 发明人 Abribat Thierry
分类号 C12N9/82;A61K38/50;A61K47/48;C12N9/96 主分类号 C12N9/82
代理机构 代理人
主权项 1. A conjugate comprising an L-asparaginase from Erwinia chrysanthemi having at least 90% sequence identity to the amino acid of SEQ ID NO:1 and conjugated to at least one polyethylene glycol (PEG) molecule, wherein the at least one PEG has a molecular weight less than or equal to 5000 Da and the conjugate has at least fifty times more in vivo L-asparaginase activity compared to an Erwinia chrysanthemi L-asparaginase not conjugated to PEG.
地址 Ecully FR